|
|
Biotech
|
|
||
Upgrades/downgrades etc
$RVNC PT Raised to $32 at Goldman Sachs
$RETA remains a top pick for 2020 at Citi. $328 PT
$AMRN to Present at Two Upcoming Investor Conferences
$DCPH reiterated with an overweight at Piper. $75 PT
$PTCT downgraded to Sector Perform from Outperform at RBC Capital. $60 PT
$PTCT downgraded to Neutral from Buy at Citi. PT raised to $71 from $55
$AEZS $4.5M ATM offering with HCW; ~3.4M Shares priced at $1.29/share
$AXGT $65M offering prices 14.03M shares at $3.75/share + offering pre-funded warrants to purchase 3.3M shares at ~$3.75/per pre funded warrant
$GLPG downgraded to Underperform from Sector Perform at RBC. $175 PT
$TVTY - Tivity Health down 39% premarket on Q4 miss, soft guidance
$BLUE PT lowered to $110 from $150 at Janney.
$ABUS initiated at Outperform at Baird. PT $8
$MESO Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic GVHD.
|
return to message board, top of board |